247 related articles for article (PubMed ID: 17695420)
1. Urinary cyclic GMP after treatment of gynecological cancer. A prognostic marker of clinical outcome.
Orbo A; Hanevik M; Jaeger R; Van Heusden S; Sager G
Anticancer Res; 2007; 27(4C):2591-6. PubMed ID: 17695420
[TBL] [Abstract][Full Text] [Related]
2. Urinary gonadotropin peptide (UGP) and serum CA 125 in gynaecologic practice, a clinical prospective study.
Schutter EM; Mijatovic V; Kok A; Van Kamp GJ; Verstraeten R; Verheijen RH
Anticancer Res; 1999; 19(6C):5551-7. PubMed ID: 10697615
[TBL] [Abstract][Full Text] [Related]
3. [Dynamics of urinary excretion of cyclic nucleotides in cancer patients during a long-term follow-up].
Bershteĭn LM
Vopr Onkol; 1987; 33(9):54-8. PubMed ID: 2821698
[TBL] [Abstract][Full Text] [Related]
4. Beta-core fragment (beta-core/UGF/UGP), a tumor marker: a 7-year report.
Cole LA; Tanaka A; Kim GS; Park SY; Koh MW; Schwartz PE; Chambers JT; Nam JH
Gynecol Oncol; 1996 Feb; 60(2):264-70. PubMed ID: 8631549
[TBL] [Abstract][Full Text] [Related]
5. Serial determinations of aminoterminal propeptide of type III procollagen (PIIINP) and prognosis in ovarian cancer; comparison to CA125.
Simojoki M; Santala M; Risteli J; Risteli L; Kauppila A
Anticancer Res; 2000; 20(6C):4655-60. PubMed ID: 11205196
[TBL] [Abstract][Full Text] [Related]
6. Relapse and survival in early-stage ovarian cancer.
Lenhard SM; Bufe A; Kümper C; Stieber P; Mayr D; Hertlein L; Kirschenhofer A; Friese K; Burges A
Arch Gynecol Obstet; 2009 Jul; 280(1):71-7. PubMed ID: 19093129
[TBL] [Abstract][Full Text] [Related]
7. Carcinoembryonic antigen messenger RNA expression in blood can predict relapse in gastric cancer.
Ishigami S; Sakamoto A; Uenosono Y; Nakajo A; Okumura H; Matsumoto M; Setoyama T; Arigami T; Uchikado Y; Arima H; Natsugoe S; Aikou T
J Surg Res; 2008 Aug; 148(2):205-9. PubMed ID: 17936797
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up study in breast cancer patients using serum tumor markers CEA and CA 15-3.
Lumachi F; Brandes AA; Boccagni P; Polistina F; Favia G; D'Amico DF
Anticancer Res; 1999; 19(5C):4485-9. PubMed ID: 10650797
[TBL] [Abstract][Full Text] [Related]
9. Early prediction of tumor recurrence after curative resection of gastric carcinoma by measuring soluble E-cadherin.
Chan AO; Chu KM; Lam SK; Cheung KL; Law S; Kwok KF; Wong WM; Yuen MF; Wong BC
Cancer; 2005 Aug; 104(4):740-6. PubMed ID: 15991243
[TBL] [Abstract][Full Text] [Related]
10. Combined use of urinary UGP and serum CA 125 in the diagnosis of gynecological cancers.
Plebani M; Navaglia F; Basso D; De Paoli M; Nicoletto MO; Maraglino E; Torre GC
Anticancer Res; 1996; 16(6B):3833-8. PubMed ID: 9042266
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of Ca 125 levels during primary therapy.
Markmann S; Gerber B; Briese V
Anticancer Res; 2007; 27(4A):1837-9. PubMed ID: 17649781
[TBL] [Abstract][Full Text] [Related]
12. Periodic measurement of serum carcinoembryonic antigen and carbohydrate antigen 15-3 levels as postoperative surveillance after breast cancer surgery.
Nakamura T; Kimura T; Umehara Y; Suzuki K; Okamoto K; Okumura T; Morizumi S; Kawabata T
Surg Today; 2005; 35(1):19-21. PubMed ID: 15622458
[TBL] [Abstract][Full Text] [Related]
13. The use of mucin-specific monoclonal antibodies and lectins in the detection of tumor-associated serum markers in gynecological cancer.
Devine PL; McGuckin MA; Ramm LE; Harada H; Ward BG
Cancer Biochem Biophys; 1993 Sep; 13(4):221-38. PubMed ID: 8521372
[TBL] [Abstract][Full Text] [Related]
14. [Usefulness of evaluation of carcinoembryonic antigen (CEA) and soluble fragments of cytokeratin 18-th (TPS) in postoperative monitoring of patients with colorectal cancer].
Sandelewski A; Kokocińska D; Partyka R; Kocot J; Starzewski J; Chanek I; Jałowiecki P
Pol Merkur Lekarski; 2005 Jun; 18(108):647-50. PubMed ID: 16124375
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of serum KL-6, a mucin-like glycoprotein, as a tumor marker for breast cancer.
Ogawa Y; Ishikawa T; Ikeda K; Nakata B; Sawada T; Ogisawa K; Kato Y; Hirakawa K
Clin Cancer Res; 2000 Oct; 6(10):4069-72. PubMed ID: 11051258
[TBL] [Abstract][Full Text] [Related]
16. Serum tumor markers may predict overall and disease specific survival in patients with clinically organ confined invasive bladder cancer.
Margel D; Tal R; Baniel J
J Urol; 2007 Dec; 178(6):2297-300; discussion 2300-1. PubMed ID: 17936837
[TBL] [Abstract][Full Text] [Related]
17. Normal and modified urinary nucleosides represent novel biomarkers for colorectal cancer diagnosis and surgery monitoring.
Feng B; Zheng MH; Zheng YF; Lu AG; Li JW; Wang ML; Ma JJ; Xu GW; Liu BY; Zhu ZG
J Gastroenterol Hepatol; 2005 Dec; 20(12):1913-9. PubMed ID: 16336453
[TBL] [Abstract][Full Text] [Related]
18. Carcinoembryonic antigen (CEA)--a useful marker for the detection of recurrent disease in endometrial carcinoma patients.
Bruns F; Micke O; Halek G; Schäfer U; Willich N
Anticancer Res; 2003; 23(2A):1103-6. PubMed ID: 12820355
[TBL] [Abstract][Full Text] [Related]
19. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.
Gadducci A; Tana R; Cosio S; Genazzani AR
Crit Rev Oncol Hematol; 2008 Apr; 66(1):10-20. PubMed ID: 17964182
[TBL] [Abstract][Full Text] [Related]
20. Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumour marker for detecting disease relapse and assessing treatment efficacy in breast cancer.
Nakata B; Takashima T; Ogawa Y; Ishikawa T; Hirakawa K
Br J Cancer; 2004 Aug; 91(5):873-8. PubMed ID: 15280913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]